Mirzaei S, Krotla G, Knoll P, Koriska K, Köhn H
Department of Nuclear Medicine, Wilhelminenspital, Vienna, Austria.
Acta Med Austriaca. 1999;26(1):29-31.
Bone mass is purportedly reduced by an excess of endogenous or exogenous thyroid hormone or perhaps by calcitonin deficiency. Patients who have undergone thyroidectomy could be subject to all of these effects. In the present study we tried to demonstrate, whether lack of calcitonin following thyroidectomy has a significant influence on bone density. We measured thyroid hormone levels, TSH and calcitonin and assessed the bone mass in the hip and lumbar spine of 55 patients (32 f, 23 m), who had undergone a subtotal thyroidectomy between 1938 and 1996 on the reason of a non-toxic goitre. TSH levels were suppressed in 16 patients. Serum concentration of total calcium, intact PTH, osteocalcin were normal in all subjects. The mean fasting calcitonin level was in the patient group 2.09 +/- 0.7 pg/ml and in the control group, age matched healthy volunteers, 2.8 +/- 1.2 pg/ml. However, the serum level of calcitonin was not significantly lower than in the control group. 43 patients had an osteopenia or osteoporosis. The interpretation of the results in this study is hampered by the fact, that in women results may be influenced by involutional osteoporosis. Therefore we focus on the potential for osteoporosis among the 23 men. The results of our study indicates, that there is a significant reduction in bone mass in male after thyroidectomy, no matter whether T4 therapy is given or not, and whether TSH is suppressed or in a normal range.
据推测,内源性或外源性甲状腺激素过多,或者可能由于降钙素缺乏,会导致骨量减少。接受甲状腺切除术的患者可能会受到所有这些影响。在本研究中,我们试图证明甲状腺切除术后降钙素缺乏是否对骨密度有显著影响。我们测量了55例患者(32例女性,23例男性)的甲状腺激素水平、促甲状腺激素(TSH)和降钙素,并评估了他们髋部和腰椎的骨量。这些患者在1938年至1996年间因非毒性甲状腺肿接受了甲状腺次全切除术。16例患者的TSH水平受到抑制。所有受试者的总钙、完整甲状旁腺激素(PTH)、骨钙素的血清浓度均正常。患者组的平均空腹降钙素水平为2.09±0.7 pg/ml,对照组为年龄匹配的健康志愿者,其平均空腹降钙素水平为2.8±1.2 pg/ml。然而,患者组的血清降钙素水平并不显著低于对照组。43例患者存在骨质减少或骨质疏松。本研究结果的解读受到以下事实的阻碍,即女性的结果可能受更年期骨质疏松症的影响。因此,我们重点关注23名男性中骨质疏松症的可能性。我们的研究结果表明,男性甲状腺切除术后骨量显著减少,无论是否给予T4治疗,以及TSH是否受到抑制或处于正常范围。